Generation Bio Co. Statistics
Total Valuation
GBIO has a market cap or net worth of $40.48 million. The enterprise value is -$14.95 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GBIO has 6.74 million shares outstanding. The number of shares has increased by 0.98% in one year.
| Current Share Class | 6.74M |
| Shares Outstanding | 6.74M |
| Shares Change (YoY) | +0.98% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 5.60% |
| Owned by Institutions (%) | 66.27% |
| Float | 4.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.92 |
| Forward PS | n/a |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.51, with a Debt / Equity ratio of 1.58.
| Current Ratio | 7.51 |
| Quick Ratio | 7.31 |
| Debt / Equity | 1.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.45% and return on invested capital (ROIC) is -26.86%.
| Return on Equity (ROE) | -85.45% |
| Return on Assets (ROA) | -21.07% |
| Return on Invested Capital (ROIC) | -26.86% |
| Return on Capital Employed (ROCE) | -46.82% |
| Revenue Per Employee | $184,609 |
| Profits Per Employee | -$629,739 |
| Employee Count | 115 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.52% in the last 52 weeks. The beta is 2.54, so GBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.54 |
| 52-Week Price Change | -72.52% |
| 50-Day Moving Average | 6.13 |
| 200-Day Moving Average | 5.31 |
| Relative Strength Index (RSI) | 48.01 |
| Average Volume (20 Days) | 44,792 |
Short Selling Information
The latest short interest is 94,890, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 94,890 |
| Short Previous Month | 124,867 |
| Short % of Shares Out | 1.41% |
| Short % of Float | 1.92% |
| Short Ratio (days to cover) | 1.85 |
Income Statement
In the last 12 months, GBIO had revenue of $21.23 million and -$72.42 million in losses. Loss per share was -$10.83.
| Revenue | 21.23M |
| Gross Profit | -26.62M |
| Operating Income | -74.95M |
| Pretax Income | -72.42M |
| Net Income | -72.42M |
| EBITDA | -70.32M |
| EBIT | -74.95M |
| Loss Per Share | -$10.83 |
Full Income StatementBalance Sheet
The company has $141.36 million in cash and $85.32 million in debt, giving a net cash position of $56.04 million or $8.32 per share.
| Cash & Cash Equivalents | 141.36M |
| Total Debt | 85.32M |
| Net Cash | 56.04M |
| Net Cash Per Share | $8.32 |
| Equity (Book Value) | 54.10M |
| Book Value Per Share | 8.03 |
| Working Capital | 126.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$80.52 million and capital expenditures -$1.17 million, giving a free cash flow of -$81.69 million.
| Operating Cash Flow | -80.52M |
| Capital Expenditures | -1.17M |
| Free Cash Flow | -81.69M |
| FCF Per Share | -$12.13 |
Full Cash Flow StatementMargins
| Gross Margin | -125.37% |
| Operating Margin | -353.02% |
| Pretax Margin | -341.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.98% |
| Shareholder Yield | -0.98% |
| Earnings Yield | -176.26% |
| FCF Yield | -198.83% |
Analyst Forecast
The average price target for GBIO is $10.67, which is 77.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.67 |
| Price Target Difference | 77.54% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | -21.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 22, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
GBIO has an Altman Z-Score of -5.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.73 |
| Piotroski F-Score | 3 |
